Download PDF
Semin Neurol 2008; 28(1): 017-028
DOI: 10.1055/s-2007-1019126
© Thieme Medical Publishers

Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention

Alberto Ascherio1 , Kassandra Munger2
  • 1Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts
  • 2Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts
Further Information

Publication History

Publication Date:
07 February 2008 (online)

    Permissions and Reprints

ABSTRACT

Although genetic susceptibility explains the clustering of multiple sclerosis (MS) within families and the sharp decline in risk with increasing genetic distance, it cannot fully explain the geographical variations in MS frequency and the changes in risk that occur with migration, which support the action of strong environmental factors. Among these, vitamin D status, infection with the Epstein-Barr virus, and cigarette smoking are emerging as the most consistent predictors of MS risk. In this article, we review the epidemiological data, critically discuss the evidence for causality of these associations, and briefly discuss the possibility of interventions to reduce MS risk.

KEYWORDS

Multiple sclerosis - epidemiology - vitamin D - infection - environment

REFERENCES

  • 1 Lassmann H, Bruck W, Lucchinetti C F. The immunopathology of multiple sclerosis: an overview.  Brain Pathol. 2007;  17 210-218
    CrossrefPubMedGoogle Scholar
  • 2 Kurtzke J F. MS epidemiology world wide. One view of current status.  Acta Neurol Scand Suppl. 1995;  161 23-33
    PubMedGoogle Scholar
  • 3 Vukusic S, Van Bockstael V, Gosselin S, Confavreux C. Regional variations of multiple sclerosis prevalence in French farmers.  J Neurol Neurosurg Psychiatry. 2007;  78 707-709
    PubMedGoogle Scholar
  • 4 Koch-Henriksen N, Hyllested K. Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry.  Acta Neurol Scand. 1988;  78 369-380
    PubMedGoogle Scholar
  • 5 Hernán M A, Olek M J, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women.  Neurology. 1999;  53 1711-1718
    CrossrefPubMedGoogle Scholar
  • 6 Orton S M, Herrera B M, Yee I M et al.. Sex ratio of multiple sclerosis in Canada: a longitudinal study.  Lancet Neurol. 2006;  5 932-936
    CrossrefPubMedGoogle Scholar
  • 7 Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up.  Mult Scler. 1999;  5 293-296
    CrossrefPubMedGoogle Scholar
  • 8 Mayr W T, Pittock S J, McClelland R L et al.. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.  Neurology. 2003;  61 1373-1377
    CrossrefPubMedGoogle Scholar
  • 9 Compston A, Coles A. Multiple sclerosis.  Lancet. 2002;  359 1221-1231
    CrossrefPubMedGoogle Scholar
  • 10 Dyment D A, Ebers G C, Sadovnick A D. Genetics of multiple sclerosis.  Lancet Neurol. 2004;  3 104-110
    PubMedGoogle Scholar
  • 11 Sawcer S, Compston A. Multiple sclerosis: light at the end of the tunnel.  Eur J Hum Genet. 2006;  14 257-258
    PubMedGoogle Scholar
  • 12 Alter M, Kahana E, Loewenson R. Migration and risk of multiple sclerosis.  Neurology. 1978;  28 1089-1093
    CrossrefPubMedGoogle Scholar
  • 13 Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age at immigration to Israel.  Arch Neurol. 1966;  15 234-237
    CrossrefPubMedGoogle Scholar
  • 14 Dean G, Kurtzke J F. On the risk of multiple sclerosis according to age at immigration to South Africa.  BMJ. 1971;  3 725-729
    CrossrefPubMedGoogle Scholar
  • 15 Hammond S R, English D R, McLeod J G. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.  Brain. 2000;  123 968-974
    CrossrefPubMedGoogle Scholar
  • 16 Kurtzke J F, Beebe G W, Norman J E. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS.  Neurology. 1985;  35 672-678
    CrossrefPubMedGoogle Scholar
  • 17 Gale C R, Martyn C N. Migrant studies in multiple sclerosis.  Prog Neurobiol. 1995;  47 425-448
    CrossrefPubMedGoogle Scholar
  • 18 Compston A, Sawcer S. Genetic analysis of multiple sclerosis.  Curr Neurol Neurosci Rep. 2002;  2 259-266
    CrossrefPubMedGoogle Scholar
  • 19 Wallin M T, Page W F, Kurtzke J F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography.  Ann Neurol. 2004;  55 65-71
    CrossrefPubMedGoogle Scholar
  • 20 Norman J E, Kurtzke J F, Beebe G W. Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis.  J Chronic Dis. 1983;  36 551-559
    CrossrefPubMedGoogle Scholar
  • 21 Acheson E D, Bachrach C A, Wright F M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables.  Acta Psychiatr Scand Suppl. 1960;  35 132-147
    CrossrefPubMedGoogle Scholar
  • 22 Sutherland J M, Tyrer J H, Eadie M J. The prevalence of multiple sclerosis in Australia.  Brain. 1962;  85 149-164
    CrossrefPubMedGoogle Scholar
  • 23 Leibowitz U, Sharon D, Alter M. Geographical considerations in multiple sclerosis.  Brain. 1967;  90 871-886
    CrossrefPubMedGoogle Scholar
  • 24 van der Mei I A, Ponsonby A L, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation.  Neuroepidemiology. 2001;  20 168-174
    CrossrefPubMedGoogle Scholar
  • 25 Kurtzke J F. On the fine structure of the distribution of multiple sclerosis.  Acta Neurol Scand. 1967;  43 257-282
    CrossrefPubMedGoogle Scholar
  • 26 Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint) Part 1: Sunlight, dietary factors and epidemiology.  Intern J Environmental Studies. 1974;  6 19-27
    PubMedGoogle Scholar
  • 27 Holick M F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease.  Am J Clin Nutr. 2004;  80 1678S-1688S
    CrossrefPubMedGoogle Scholar
  • 28 Webb A R, Kline L, Holick M F. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin.  J Clin Endocrinol Metab. 1988;  67 373-378
    CrossrefPubMedGoogle Scholar
  • 29 McKenna M J, Freaney R, Byrne P et al.. Safety and efficacy of increasing wintertime vitamin D and calcium intake by milk fortification.  QJM. 1995;  88 895-898
    PubMedGoogle Scholar
  • 30 Rockell J E, Skeaff C M, Williams S M, Green T J. Serum 25-hydroxyvitamin D concentrations of New Zealanders aged 15 years and older.  Osteoporos Int. 2006;  17 1382-1389
    CrossrefPubMedGoogle Scholar
  • 31 Swank R L, Lerstad O, Strøm A, Backer J. Multiple sclerosis in rural Norway: its geographic and occupational incidence in relation to nutrition.  N Engl J Med. 1952;  246 722-728
    PubMedGoogle Scholar
  • 32 Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway.  Acta Neurol Scand. 1970;  46 455-483
    CrossrefPubMedGoogle Scholar
  • 33 Freedman D M, Dosemeci M, Alavanja M C. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates.  Occup Environ Med. 2000;  57 418-421
    CrossrefPubMedGoogle Scholar
  • 34 Goldacre M J, Seagroatt V, Yeates D, Acheson E D. Skin cancer in people with multiple sclerosis: a record linkage study.  J Epidemiol Community Health. 2004;  58 142-144
    CrossrefPubMedGoogle Scholar
  • 35 Antonovsky A, Leibowitz U, Smith H A et al.. Epidemiologic study of multiple sclerosis in Israel.  Arch Neurol. 1965;  13 183-193
    CrossrefPubMedGoogle Scholar
  • 36 Cendrowski W, Wender M, Dominik W et al.. Epidemiological study of multiple sclerosis in western Poland.  Eur Neurol. 1969;  2 90-108
    CrossrefPubMedGoogle Scholar
  • 37 van der Mei I AF, Ponsonby A L, Dwyer T et al.. Past exposure to sun, skin phenotype and risk of multiple sclerosis: a case-control study.  BMJ. 2003;  327 316-321
    CrossrefPubMedGoogle Scholar
  • 38 van der Mei I A, Blizzard L, Ponsonby A L, Dwyer T. Validity and reliability of adult recall of past sun exposure in a case-control study of multiple sclerosis.  Cancer Epidemiol Biomarkers Prev. 2006;  15 1538-1544
    CrossrefPubMedGoogle Scholar
  • 39 Kampman M T, Wilsgaard T, Mellgren S I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle.  J Neurol. 2007;  254 471-477
    CrossrefPubMedGoogle Scholar
  • 40 Willett W C. Nutritional Epidemiology. 2nd ed. New York; Oxford University Press Inc 1998
    Google Scholar
  • 41 Munger K L, Zhang S M, O'Reilly E et al.. Vitamin D intake and incidence of multiple sclerosis.  Neurology. 2004;  62 60-65
    CrossrefPubMedGoogle Scholar
  • 42 Willett W C, Sampson L, Browne M L et al.. The use of a self-administered questionnaire to assess diet four years in the past.  Am J Epidemiol. 1988;  127 188-199
    CrossrefPubMedGoogle Scholar
  • 43 Salvini S, Hunter D J, Sampson L et al.. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption.  Int J Epidemiol. 1989;  18 858-867
    CrossrefPubMedGoogle Scholar
  • 44 Feskanich D, Willett W C, Colditz G A. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women.  Am J Clin Nutr. 2003;  77 504-511
    PubMedGoogle Scholar
  • 45 Levin L I, Munger K L, Rubertone M V et al.. Temporal relationship between elevation of Epstein Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.  JAMA. 2005;  293 2496-2500
    CrossrefPubMedGoogle Scholar
  • 46 Munger K L, Levin L I, Hollis B W, Howard N S, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.  JAMA. 2006;  296 2832-2838
    CrossrefPubMedGoogle Scholar
  • 47 Lucas R M, Ponsonby A L. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation?.  Prog Biophys Mol Biol. 2006;  92 140-149
    CrossrefPubMedGoogle Scholar
  • 48 Lemire J M, Archer D C. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis.  J Clin Invest. 1991;  87 1103-1107
    PubMedGoogle Scholar
  • 49 Cantorna M T, Hayes C E, DeLuca H F. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis.  Proc Natl Acad Sci U S A. 1996;  93 7861-7864
    CrossrefPubMedGoogle Scholar
  • 50 Cantorna M T, Hayes C E, DeLuca H F. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis.  Proc Natl Acad Sci U S A. 1996;  93 7861-7864
    CrossrefPubMedGoogle Scholar
  • 51 Hayes C E, Nashold F E, Spach K M, Pedersen L B. The immunological functions of the vitamin D endocrine system.  Cell Mol Biol. 2003;  49 277-300
    PubMedGoogle Scholar
  • 52 Hayes C E, Cantorna M T, DeLuca H F. Vitamin D and multiple sclerosis.  Proc Soc Exp Biol Med. 1997;  216 21-27
    PubMedGoogle Scholar
  • 53 Meehan T F, DeLuca H F. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice.  Arch Biochem Biophys. 2002;  408 200-204
    CrossrefPubMedGoogle Scholar
  • 54 Spach K M, Hayes C E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice.  J Immunol. 2005;  175 4119-4126
    PubMedGoogle Scholar
  • 55 Nashold F E, Hoag K A, Goverman J, Hayes C E. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis.  J Neuroimmunol. 2001;  119 16-29
    CrossrefPubMedGoogle Scholar
  • 56 Hayes C E, Nashold F E, Spach K M, Pedersen L B. The immunological functions of the vitamin D endocrine system.  Cell Mol Biol (Noisy-le-grand). 2003;  49 277-300
    PubMedGoogle Scholar
  • 57 Hollis B W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D.  J Nutr. 2005;  135 317-322
    PubMedGoogle Scholar
  • 58 Dawson-Hughes B, Heaney R P, Holick M F et al.. Estimates of optimal vitamin D status.  Osteoporos Int. 2005;  16 713-716
    CrossrefPubMedGoogle Scholar
  • 59 Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.  Am J Clin Nutr. 1999;  69 842-856
    CrossrefPubMedGoogle Scholar
  • 60 Heaney R P, Davies K M, Chen T C, Holick M F, Barger-Lux M J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol.  Am J Clin Nutr. 2003;  77 204-210
    PubMedGoogle Scholar
  • 61 Standing Committee on the Scientific Evaluation of Dietary Reference Intakes FaNB, Institute of Medicine .Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC; National Academy Press 1997
    Google Scholar
  • 62 Bischoff-Ferrari H A, Giovannucci E, Willett W C, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.  Am J Clin Nutr. 2006;  84 18-28
    CrossrefPubMedGoogle Scholar
  • 63 Looker A C, Dawson-Hughes B, Calvo M S, Gunter E W, Sahyoun N R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III.  Bone. 2002;  30 771-777
    CrossrefPubMedGoogle Scholar
  • 64 Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors.  Am J Clin Nutr. 2007;  85 860-868
    PubMedGoogle Scholar
  • 65 Poskanzer D C, Schapira K, Miller H. Multiple sclerosis and poliomyelitis.  Lancet. 1963;  2 917-921
    PubMedGoogle Scholar
  • 66 Leibowitz U, Antonovsky A, Medalie J M et al.. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation.  J Neurol Neurosurg Psychiatry. 1966;  29 60-68
    PubMedGoogle Scholar
  • 67 Beebe G W, Kurtzke J F, Kurland L T, Auth T L, Nagler B. Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the Army experience in World War II.  Neurology. 1967;  17 1-17
    PubMedGoogle Scholar
  • 68 Russell W R. Multiple sclerosis: occupation and social group at onset.  Lancet. 1971;  2 832-834
    PubMedGoogle Scholar
  • 69 Sewell D L, Reinke E K, Hogan L H, Sandor M, Fabry Z. Immunoregulation of CNS autoimmunity by helminth and mycobacterial infections.  Immunol Lett. 2002;  82 101-110
    CrossrefPubMedGoogle Scholar
  • 70 Bach J F. The effect of infections on susceptibility to autoimmune and allergic diseases.  N Engl J Med. 2002;  347 911-920
    CrossrefPubMedGoogle Scholar
  • 71 Maizels R M, Bundy D A, Selkirk M E, Smith D F, Anderson R M. Immunological modulation and evasion by helminth parasites in human populations.  Nature. 1993;  365 797-805
    CrossrefPubMedGoogle Scholar
  • 72 Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis.  Ann Neurol. 2007;  61 97-108
    CrossrefPubMedGoogle Scholar
  • 73 Fleming J, Fabry Z. The hygiene hypothesis and multiple sclerosis.  Ann Neurol. 2007;  61 85-89
    CrossrefPubMedGoogle Scholar
  • 74 Niederman J C, Evans A S. Epstein-Barr virus. In: Evans AS, Kaslow RA Viral Infections of Humans: Epidemiology and Control. 4th ed. New York; Plenum Medical Book Company 1997: 253-283
    Google Scholar
  • 75 Takeuchi K, Tanaka-Taya K, Kazuyama Y et al.. Prevalence of Epstein-Barr virus in Japan: trends and future prediction.  Pathol Int. 2006;  56 112-116
    CrossrefPubMedGoogle Scholar
  • 76 Kurtzke J F. Multiple sclerosis in time and space: geographic clues to cause.  J Neurovirol. 2000;  6(suppl 2) S134-S140
    PubMedGoogle Scholar
  • 77 Warner H B, Carp R I. Multiple sclerosis and Epstein-Barr virus.  Lancet. 1981;  2 1290
    PubMedGoogle Scholar
  • 78 Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis.  Epidemiology. 2000;  11 220-224
    CrossrefPubMedGoogle Scholar
  • 79 Ascherio A, Munger K L. Environmental risk factors for multiple sclerosis. Part I: The role of infection.  Ann Neurol. 2007;  61 288-299
    CrossrefPubMedGoogle Scholar
  • 80 Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis.  JAMA. 2004;  291 1875-1879
    CrossrefPubMedGoogle Scholar
  • 81 Pohl D, Krone B, Rostasy K et al.. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis.  Neurology. 2006;  67 2063-2065
    CrossrefPubMedGoogle Scholar
  • 82 Thacker E L, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis.  Ann Neurol. 2006;  59 499-503
    CrossrefPubMedGoogle Scholar
  • 83 Nielsen T R, Rostgaard K, Nielsen N M et al.. Multiple sclerosis after infectious mononucleosis.  Arch Neurol. 2007;  64 72-75
    CrossrefPubMedGoogle Scholar
  • 84 Cook S D. Does Epstein Barr virus cause multiple sclerosis?.  Rev Neurol Dis. 2004;  1 115-123
    PubMedGoogle Scholar
  • 85 James J A, Harley J B, Scofield R H. Epstein-Barr virus and systemic lupus erythematosus.  Curr Opin Rheumatol. 2006;  18 462-467
    CrossrefPubMedGoogle Scholar
  • 86 Serafini B, Rosicarelli B, Franciotta D et al.. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.  J Exp Med. 2007;  204 2899-2912
    CrossrefPubMedGoogle Scholar
  • 87 Ascherio A, Munger K L, Lennette E T et al.. Epstein Barr virus antibodies and risk of multiple sclerosis: a prospective study.  JAMA. 2001;  286 3083-3088
    CrossrefPubMedGoogle Scholar
  • 88 DeLorenze G N, Munger K L, Lennette E et al.. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up.  Arch Neurol. 2006;  63 839-844
    CrossrefPubMedGoogle Scholar
  • 89 Sundstrom P, Juto P, Wadell G et al.. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.  Neurology. 2004;  62 2277-2282
    CrossrefPubMedGoogle Scholar
  • 90 Lennette E T, Rymo L, Yadav M et al.. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6.  Eur J Cancer. 1993;  29A 1584-1589
    PubMedGoogle Scholar
  • 91 Kusunoki Y, Huang H, Fukuda Y et al.. A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals.  Microbiol Immunol. 1993;  37 461-469
    CrossrefPubMedGoogle Scholar
  • 92 Lunemann J D, Edwards N, Muraro P A et al.. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.  Brain. 2006;  129 1493-1506
    CrossrefPubMedGoogle Scholar
  • 93 Cepok S, Zhou D, Srivastava R et al.. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis.  J Clin Invest. 2005;  115 1352-1360
    CrossrefPubMedGoogle Scholar
  • 94 Kurtzke J F, Heltberg A. Multiple sclerosis in the Faroe Islands: an epitome.  J Clin Epidemiol. 2001;  54 1-22
    CrossrefPubMedGoogle Scholar
  • 95 Lycke J, Svennerholm B, Hjelmquist E et al.. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.  J Neurol. 1996;  243 214-224
    CrossrefPubMedGoogle Scholar
  • 96 Friedman J E, Zabriskie J B, Plank C et al.. A randomized clinical trial of valacyclovir in multiple sclerosis.  Mult Scler. 2005;  11 286-295
    CrossrefPubMedGoogle Scholar
  • 97 Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis.  Can J Public Health. 2001;  92 281-285
    PubMedGoogle Scholar
  • 98 Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy.  Acta Neurol Scand. 2002;  105 77-82
    CrossrefPubMedGoogle Scholar
  • 99 Riise T, Nortvedt M W, Ascherio A. Smoking is a risk factor for multiple sclerosis.  Neurology. 2003;  61 1122-1124
    CrossrefPubMedGoogle Scholar
  • 100 Villard-Mackintosh L, Vessey M P. Oral contraceptives and reproductive factors in multiple sclerosis incidence.  Contraception. 1993;  47 161-168
    CrossrefPubMedGoogle Scholar
  • 101 Thorogood M, Hannaford P C. The influence of oral contraceptives on the risk of multiple sclerosis.  Br J Obstet Gynaecol. 1998;  105 1296-1299
    CrossrefPubMedGoogle Scholar
  • 102 Hernán M A, Olek M J, Ascherio A. Cigarette smoking and incidence of multiple sclerosis.  Am J Epidemiol. 2001;  154 69-74
    CrossrefPubMedGoogle Scholar
  • 103 Hernán M A, Jick S S, Logroscino G, Olek M J, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis.  Brain. 2005;  128 1461-1465
    CrossrefPubMedGoogle Scholar
  • 104 Ascherio A, Munger K L. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors.  Ann Neurol. 2007;  61 504-513
    CrossrefPubMedGoogle Scholar
  • 105 Courville C B, Maschmeyer J E, DeLay C P. Effects of smoking on the acute exacerbations of multiple sclerosis.  Bull Los Angeles Neurol Soc. 1964;  29 1-6
    PubMedGoogle Scholar
  • 106 Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis.  Arch Neurol. 1992;  49 1243-1247
    CrossrefPubMedGoogle Scholar
  • 107 Costenbader K H, Karlson E W. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?.  Lupus. 2006;  15 737-745
    CrossrefPubMedGoogle Scholar
  • 108 Hawkins B T, Brown R C, Davis T P. Smoking and ischemic stroke: a role for nicotine?.  Trends Pharmacol Sci. 2002;  23 78-82
    CrossrefPubMedGoogle Scholar
  • 109 Vleeming W, Rambali B, Opperhuizen A. The role of nitric oxide in cigarette smoking and nicotine addiction.  Nicotine Tob Res. 2002;  4 341-348
    PubMedGoogle Scholar
  • 110 Hooper D C, Bagasra O, Marini J C et al.. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis.  Proc Natl Acad Sci U S A. 1997;  94 2528-2533
    CrossrefPubMedGoogle Scholar
  • 111 Rejdak K, Eikelenboom M J, Petzold A et al.. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.  Neurology. 2004;  63 1439-1445
    PubMedGoogle Scholar
  • 112 Fryar C D, Hirsch R, Porter K S et al.. Smoking and alcohol behaviors reported by adults, United States, 1999-2002 [online]. Available at: http://www.cdc.gov/nchs/data/ad/ad378.pdf
    Google Scholar
  • 113 Rothman K, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia; Lippincott-Raven Publishers 1998
    Google Scholar

Alberto AscherioM.D. Dr.P.H. 

Departments of Nutrition and Epidemiology, Harvard School of Public Health

655 Huntington Avenue, Boston, MA 02115

Email: aascheri@hsph.harvard.edu

      >